首页> 外文OA文献 >PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

【2h】

PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

机译：PCN97成本效益分析：使用曲妥珠单抗+纳曲唑与拉帕替尼+左唑，左雷唑单药治疗或阿那曲唑单药疗法治疗HER2 + /激素受体阳性（HR +）转移性肝癌转移服务（NHS）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
McNamara S; Moore L; Ray J;
展开▼
作者单位

展开▼
年度 2010
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC) [J] . RiemsmaR., ForbesC.A., AmonkarM.M., Current medical research and opinion . 2012,第8期

机译：拉帕替尼联合来曲唑与其他一线治疗激素受体阳性（HR +）和HER2 +晚期或转移性乳腺癌（MBC）的系统评价
2. 5048 A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR+) metastatic breast cancer (MBC) [J] . B.Sherrill, M.Amonkar, B.Sherif, European Journal of Cancer Supplements . 2009,第2期

机译：5048拉帕替尼加来曲唑与单独使用来曲唑比较作为激素受体阳性（HR +）转移性乳腺癌（MBC）的一线治疗的Q-TWiST分析
3. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial [J] . HuoberJ., FaschingP.A., BarsoumM., The Breast : . 2012,第1期

机译：来曲唑联合曲妥珠单抗作为HER2阳性，激素受体阳性转移性乳腺癌患者的一线治疗相比，来曲唑单药治疗的疗效更高-eLEcTRA试验结果
4. Quality of Life in Hormone Receptor–Positive HER-2+ Metastatic Breast Cancer Patients During Treatment with Letrozole Alone or in Combination with Lapatinib [O] . Beth Sherrill, Mayur M. Amonkar, Bintu Sherif, 2010

机译：单独使用来曲唑或联合拉帕替尼治疗期间激素受体阳性HER-2 +转移性乳腺癌患者的生活质量
5. PCN15 SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ ADVANCED OR METASTATIC BREAST CANCER (MBC) [O] . Riemsma R, Forbes CA, Amonkar M, 2010

机译：PCN15系统评价拉帕替尼加左唑与其他一线治疗激素阳性（HR +）HER2 +晚期或转移性乳腺癌（MBC）

著录项

相似文献

相关主题

期刊订阅